VIP (Vasoactive Intestinal Peptide) as a New Approach to Treating Autoimmune Disease
VIP demonstrates potent anti-inflammatory and immunosuppressive properties through regulatory T-cell generation and dendritic cell tolerization, positioning it as a novel autoimmune therapy — from arthritis to multiple sclerosis.
Quick Facts
What This Study Found
VIP generates regulatory T-cells, tolerizes dendritic cells, and suppresses Th1/Th17 inflammatory pathways, providing a comprehensive anti-autoimmune mechanism applicable to rheumatoid arthritis, MS, type 1 diabetes, and transplant rejection.
Key Numbers
How They Did This
review study on neuropeptides, inflammation.
Why This Research Matters
Relevant for neuropeptides, inflammation, immune-function.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding VIP generates regulatory T-cells, tolerizes dendritic cells, and suppresses Th1/Th17 inflammatory pathways, providing a comprehensive anti-autoimmune
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2007.
- Original Title:
- Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.
- Published In:
- Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii70-6 (2007)
- Authors:
- Gonzalez-Rey, Elena(7), Anderson, Per(4), Delgado, Mario(10)
- Database ID:
- RPEP-01233
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What was studied?
VIP (Vasoactive Intestinal Peptide) as a New Approach to Treating Autoimmune Disease
What was found?
VIP demonstrates potent anti-inflammatory and immunosuppressive properties through regulatory T-cell generation and dendritic cell tolerization, positioning it as a novel autoimmune therapy — from arthritis to multiple sclerosis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01233APA
Gonzalez-Rey, Elena; Anderson, Per; Delgado, Mario. (2007). Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.. Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii70-6.
MLA
Gonzalez-Rey, Elena, et al. "Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.." Annals of the rheumatic diseases, 2007.
RethinkPeptides
RethinkPeptides Research Database. "Emerging roles of vasoactive intestinal peptide: a new appro..." RPEP-01233. Retrieved from https://rethinkpeptides.com/research/gonzalez-rey-2007-emerging-roles-of-vasoactive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.